CRISPR Therapeutics AG (CRSP)

From the record

CRISPR Therapeutics AG's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

CRISPR Therapeutics AG's 8 filed years say what it did: revenue went from $3 million in fiscal 2018 to $4 million in fiscal 2025, up 1.7% a year; it rose in 3 of 7 years; the deepest fall was 100% from fiscal 2021 to fiscal 2022; net income was positive in 2 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, CRISPR Therapeutics AG lost about 30 cents for every dollar of shareholders' money. Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 6.6% over the year (the filed statements).

From the record

CRISPR Therapeutics AG's standing among 102 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 28% by size; a net margin of -16569.8% ranks in the bottom 10%; revenue growth of 43.1% a year over the last 3 filed years ranks in the top 23% (its annual reports).

From the record

CRISPR Therapeutics AG's leadership, from its insiders' filings and its current reports: the chief executive on the record is Kulkarni, Samarth (Chief Executive Officer, as filed), filing under that title since 2017-12-05, 8.9 years (top 14% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 34%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 36%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

CRISPR Therapeutics AG's room to grow, from the newest filed statements (fiscal 2025): cash of $348 million against no long-term debt tagged leaves 15.3% of its assets as net cash, bottom 25% of its family; cash from operations less capital spending is -9855.5% of revenue (bottom 9%); research spending of 8114.1% of revenue (top 8%) (its annual report).

From the record

CRISPR Therapeutics AG's growth drivers, from the filed years to fiscal 2025: revenue grew 43.1% a year over the last three filed years against 1.7% over all 8, speeding up (top 9% of its family); the newest year grew -90.6% (bottom 1%); research spending grew -14.9% a year (bottom 21%); capital spending grew -70.9% a year (bottom 6%) (its annual reports). CRISPR Therapeutics AG tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

CRISPR Therapeutics AG's newest year against its own record: revenue of $4 million in fiscal 2025 came in 98.3% below the $208 million its prior three years' pace pointed to (bottom 1% of its family); net income of $582 million against a prior three-year average of $390 million (bottom 18%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 13%) (its annual reports).